Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > G12D/G12V KRAS mutation in PC & CRC patients respond to Pela

<< Previous

Bullboard Posts

Next >>

Comment by CMHarring218431on Jul 26, 2024 10:40am

146 Views

Post# 36149746

RE:RE:RE:RE:RE:RE:RE:G12D/G12V KRAS mutation in PC & CRC patients respond to Pela

Very interesting that you mention Dr Sanjay Goel. Because of him I take a daily supplement of French grape seed extract. He and his team have studied and reported remarkable test results that show this particular extract helps prevent cancers, protects the heart, and strengthens the immune system. Sounds like what you hear about blueberries etc... but he claims it is many, many more times powerful. I also combine it with curcumin for a double whammy

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing